Stryker price target raised to $257 from $239 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Stryker to $257 from $239 and keeps an Overweight rating on the shares. The analyst says his upside sum-of-the-parts analysis and "compelling" share trend analysis provide evidence of "robust" multi-year gains and raises his conviction in Stryker’s thesis. He sees a "potentially banner year ahead" for Stryker, driven by continued robot-driven share gains and two major MedSurg product launches in 2023.